Biognosys and the Michael J. Fox Foundation for Parkinson’s Research (MJFF) announced a collaboration to develop targeted mass spectrometry biomarker assays for Parkinson’s disease drug development. The work will focus on measuring LRRK2, the most common genetic risk factor for late-onset Parkinson’s and a major therapeutic target. Biognosys will use SISCAPA and TrueSignature targeted proteomics methods to create highly sensitive assays intended to support MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE), which includes more than 50 academic, industry, and clinical partners. Both parties said improved tools for target engagement and biological response could reduce clinical trial uncertainty.